迈瑞医疗：前三季度国际业务增长12%，欧洲市场同比增长超过20%

Core Viewpoint - The company, Mindray Medical, is addressing concerns regarding potential global economic recession and trade tensions, emphasizing its growth strategy in international markets, particularly in Europe, where it has seen significant growth despite macroeconomic challenges [1]. Group 1: International Market Performance - In the first three quarters of the year, the company's international business faced challenges due to macroeconomic changes and geopolitical conflicts, but it achieved a year-on-year growth of 12% in international business in Q3, with European market growth exceeding 20% [1]. - The international market capacity is estimated to be 4-5 times larger than that of China, with the company's average market share in international business being less than 3%, and only 1% in the in vitro diagnostics sector, indicating substantial growth potential [1]. Group 2: Strategic Response to Trade Tensions - The company has developed a clear strategy to address current international challenges, focusing on localization as a core strategy. This includes enhancing local platform construction and increasing marketing coverage [1]. - The company plans to accelerate the establishment of overseas local production platforms to mitigate high tariffs and trade barriers, with the number of planned countries for local production increasing to 14, of which 11 have already initiated local production [1]. Group 3: Resource Allocation and Market Penetration - To enhance its presence in international high-end strategic hospitals and large sample laboratories, the company will continue to allocate resources to ensure investment in international markets and accelerate the deployment of its digital solutions abroad [1].